FDA Resurrects Park Doctrine in Enforcement of Pharmaceutical GMPs

FDA is following through on earlier threats to dust off the long-dormant Park doctrine for holding chief executive officers of pharmaceutical companies personally accountable for manufacturing problems.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet